SCHEMBL23218556

SCHEMBL23218556

CCOC(=O)Cc1ccccc1OCc1coc2ccc(-c3cccc(CN)c3F)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 5/20 0.42
MEN1 O00255 3/20 0.37
POLB P06746 3/20 0.37
KMT2A Q03164 3/20 0.37
PLG P00747 1/20 0.37
PLAU P00749 1/20 0.37
F11 P03951 1/20 0.37
KLKB1 P03952 1/20 0.37
F7 P08709 1/20 0.37
TPSB2 P20231 1/20 0.37
TBXAS1 P24557 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
TGFBR1 P36897 1/20 0.35
MAPT P10636 3/20 0.35
GAA P10253 2/20 0.35
ALDH2 P05091 1/20 0.35
DPP4 P27487 1/20 0.34
MCL1 Q07820 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852904 1.00 CFD (0.42) CFDMEN1POLBKMT2APLG
SCHEMBL23218335 0.94 CFD (0.37) CFDMEN1POLBKMT2ANPSR1
SCHEMBL29852715 0.94 CFD (0.37) CFDMEN1POLBKMT2ANPSR1
SCHEMBL29852567 0.93 CFD (0.42) CFDMEN1POLBKMT2APLG
SCHEMBL23218386 0.93 CFD (0.42) CFDMEN1POLBKMT2APLG
SCHEMBL23218397 0.91 CFD (0.38) CFDMEN1POLBKMT2AMAPT
SCHEMBL29852372 0.91 CFD (0.38) CFDMEN1POLBKMT2AMAPT
SCHEMBL23219111 0.90 TSHR (0.39) MEN1POLBKMT2AMAPTALDH2
SCHEMBL29852466 0.90 TSHR (0.39) MEN1POLBKMT2AMAPTALDH2
SCHEMBL23218524 0.89 ALDH2 (0.34) CFDMEN1POLBKMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885MEN1 1819/4885POLB 3530/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885MEN1 548/4885POLB 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.